Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07831226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 10 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 28 words
    • Study title revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the control.
Trial Details
NCT Number NCT07831226
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions
(from sponsor)		 Malaria Vaccine
Related terms Malaria, Malaria, Falciparum, Malaria, Vivax
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov